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Small molecule enzyme inhibitors
In recent years, the rate of accumulation of genomic sequence information has rapidly
accelerated, culminating in the sequencing of the human genome. This information has aided in
the identification of genes whose products could serve as targets for pharmacological
intervention. Although the accumulation of sequence information has been rapid, functional
information for the corresponding gene products has lagged behind. For example, 40% of the
open reading frames in Escherichia coli encode proteins of unknown function, even though
this microbe has been scrutinised for decades. This lack of functional information makes it
difficult to develop assays to exploit these genes as potential drug targets. Techniques and
tools to facilitate the screening process independent of functional assays are needed to
efficiently exploit available targets. A combinatorial approach was used to synthesise peptide
libraries with a complexity of more than 5 x 108 members per library, arising from either 7- or
12-residue peptides in a random 12-mer library, or random 11-residue peptides in which the
central residue of each library was fixed with a different residue (Detection of small-molecule
enzyme inhibitors with peptides isolated from phage-displayed combinatorial peptide libraries
Chemistry & Biology, 7, (2000), 17-25). A broad range of enzymes were selected as targets
for phage display and a series of peptides isolated that bound specifically to each target. This
methodology is useful in formatting assays for enzyme targets. The active peptides identified
can be used in simple competitive binding assays to identify small-molecule inhibitors of
enzyme function, targeting the same functional sites on enzymes to which effective therapeutic
agents must be targeted. The binding assay can be used with a variety of detection systems and
is readily adaptable to automation, making this platform suitable for high-throughput screening
of compound libraries for drug discovery.
--------------------------------------------------------------------------------------------------------------
Antibacterial compounds
Gram positive bacteria have become increasingly resistant to antimicrobial agents and multi-
drug resistant bacterial pathogens have now become a major problem in clinical medicine. S.
aureus is a common human pathogen that has become increasingly difficult to treat because of
resistance to antimicrobial agents. Vancomycin remains the main antimicrobial treatment for
infections caused by S. aureus strains that are resistant to pencillinase-resistant antibiotics. The
emergence of vancomycin-resistant Enterococcus species raises the threat of possible transfer
of resistance factors to S. aureus. Vancomycin-resistant Stapylococcus clinical isolates have
already been discovered in Japan. There is, therefore, a need for new antimicrobial agents. A
solution phase approach was used to identify compounds which have novel antibacterial
activity (Solution-phase synthesis of a 1,5-dialkylamino-2,4-dinitrobenzene library and the
identification of novel antibacterial compounds from this library, K. S. Lam et. al., J. Comb.
Chem., 2, (2000), 467-474). A library of 4900 compounds was prepared in mixtures of 10
from a solution phase sequential displacement of two fluorines on the 1,5-difluoro-2,4-
dinitrobenzene core library template using a set of 70 amines. The mixtures of 10 were tested
for antibacterial activity against Staphylococcus aureus and Enterococcus faecalis which
identified several active mixtures. All compounds contained within the mixtures were
resynthesised as single compounds and re-tested. One of the most potent compounds isolated
was (i) which possessed a minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) against S. aureus of 11.09 and 22.18 µg/mL respectively, and an MIC
and MBC against E. faecalis of 5.5 and 11.0 µg /mL respectively. This work may therefore
prove useful in the further optimisation of the lead compounds identified in this library for the
production of even more potent novel antibacterial agents.
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